Lamarque M, Raynaud S, Itzykson R, et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood. 2012;120(25):5084-5085.

On page 5084 in the 13 December 2012 issue, there are errors in Table 1. In the column “OS, mo,” the entries corresponding to rows “<50” and “>100” are transposed, which suggests that patients with low platelet count had a longer survival than patients with high platelet count. The incorrect entries read “20.3” and “9.7,” respectively. These 2 entries should have read “9.7” and “20.3,” respectively. The corrected Table 1 is shown.

4. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.